LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

41.84 -2.13

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.75

Max

43.61

Põhinäitajad
By Trading Economics
Sissetulek	-14M -105M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	-15M -104M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+29.9% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-13M 3.3B
Eelmine avamishind	43.97
Eelmine sulgemishind	41.84

Uudiste sentiment

By Acuity

25%

75%

64 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. märts 2026, 23:01 UTC

Tulu

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5. märts 2026, 21:54 UTC

Tulu

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5. märts 2026, 21:35 UTC

Suurimad hinnamuutused turgudel

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5. märts 2026, 23:46 UTC

Market Talk

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5. märts 2026, 23:33 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5. märts 2026, 23:27 UTC

Market Talk

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5. märts 2026, 22:54 UTC

Market Talk

Tulu

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5. märts 2026, 22:50 UTC

Market Talk

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5. märts 2026, 22:48 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5. märts 2026, 22:46 UTC

Tulu

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5. märts 2026, 22:44 UTC

Tulu

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5. märts 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. märts 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

5. märts 2026, 21:35 UTC

Tulu

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5. märts 2026, 21:32 UTC

Tulu

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5. märts 2026, 21:26 UTC

Tulu

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5. märts 2026, 21:24 UTC

Tulu

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5. märts 2026, 21:23 UTC

Tulu

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5. märts 2026, 21:22 UTC

Tulu

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5. märts 2026, 21:21 UTC

Tulu

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5. märts 2026, 21:21 UTC

Tulu

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5. märts 2026, 21:20 UTC

Tulu

Costco February Net Sales Were $21.69 B >COST

5. märts 2026, 21:20 UTC

Tulu

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5. märts 2026, 21:20 UTC

Tulu

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5. märts 2026, 21:19 UTC

Tulu

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5. märts 2026, 21:18 UTC

Tulu

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5. märts 2026, 21:18 UTC

Tulu

Costco 2Q Same-Store Sales Up 7.4% >COST

5. märts 2026, 21:15 UTC

Tulu

Costco 2Q EPS $4.58 >COST

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

29.9% tõus

12 kuu keskmine prognoos

Keskmine 55.92 USD 29.9%

Kõrge 66 USD

Madal 44 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

64 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.